Sara Tolaney
@stolaney1
Followers
10,041
Following
625
Media
313
Statuses
3,135
Chief, Division of Breast Oncology @DanaFarber Tennis fan Mother of two teenage girls
Boston. MA
Joined December 2015
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
WIN FANCON IN HK
• 151058 Tweets
CONGRATS LISA
• 113359 Tweets
Manchester United
• 110636 Tweets
#MonacoGP
• 98324 Tweets
#withMUSIC
• 89033 Tweets
Perez
• 71034 Tweets
ダービー
• 65644 Tweets
Manchester City
• 60213 Tweets
Feliz 25
• 55214 Tweets
Man United
• 53026 Tweets
FAYEYOKO IZEMARISSA
• 45592 Tweets
#FACupFinal
• 43036 Tweets
May Patrick Joys Live🪽
• 41598 Tweets
攻殻機動隊
• 40801 Tweets
Mancity
• 40089 Tweets
#東京タワー
• 39783 Tweets
コミティア
• 33327 Tweets
Viva la Patria
• 31932 Tweets
#Venue101
• 14350 Tweets
消費税減税
• 13134 Tweets
マリノス
• 12726 Tweets
Revolución de Mayo
• 12534 Tweets
ジャスティンミラノ
• 12216 Tweets
Checo
• 10503 Tweets
Excited to see Destiny Breast 03 now published in NEJM! T-DXd is the current 2L standard of care for metastatic HER2+ breast cancer, and more to come from this agent in the future!
@OncoAlert
#bcsm
6
96
377
Incredible review on ER+ disease by
@DrHBurstein
in NEJM-- with beautiful figures too!
#bcsm
@OncoAlert
#NEJM
@DanaFarber
3
97
330
Breathtaking results from DB04 presented by Shaun Modi. Benefit for T-DXd irrespective of subtype & 1+/2+ IHC results
A paradigm shift that breaks through traditional subgroup classification deserving of the standing ovation!!!
#ASCO22
@OncoAlert
1
62
277
DB-03: TDxd dramatically better than T-DM1 (HR 0.28)- complete responses in 16%! New 2L stnd of care.
TDxd is revolutionizing outcomes for metastatic HER2+ dz
Brilliant presentation by
@JavierCortesMD
3
86
262
KN522: Benefit of pembro seen regardless of stage or nodal status in early stage TNBC
@OncoAlert
#SABCS21
2
84
235
RxPONDER: no benefit to chemo in postmenopausal pts 0-3 LNs RS 0-25; premenopausal pts benefited from chemo; 46% decrease in IDFS events; 53% decrease in deaths, 5-year OS absolute improvement of 1.3%; is this impact of suppression of ovarian fxn from chemo?
#SABCS20
@OncoAlert
6
90
228
Adjuvant olaparib x 1yr improves iDFS in pts with high risk breast cancer and gBRCAm!
👉3 yr iDFS 85.9% vs 77.1% (HR 0.58)-- absolute difference 8.8%.
👉Genetic testing should be offered to early stage pts
@OncoAlert
#bcsm
7
72
223
Positive data for tesetaxel (oral taxane) in metastatic HR+ breast cancer announced! The CONTESSA trial Achieved its Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved PFS Versus Capecitabine Alone (Hazard Ratio=0.716; p=0.003; 9.8 vs 6.9 mo)
5
74
208
monarchE: Results from cohort 1 (91% of pts were in cohort 1)
HR 0.68
Benefit of adjuvant abemaciclib in high risk HR+ breast cancer seen
@OncoAlert
#ESMOBreast2022
2
72
205
TROPICS-02 Overall Survival data now published in The Lancet!
Sacituzumab govitecan improved PFS, ORR, OS, & QOL c/w TPC in pts with pretreated metastatic HR+ BC. Benefit seen across all Trop-2 exp levels.
@DFCI_BreastOnc
@OncoAlert
#bcsm
2
74
201
Important study: DESTINY-Breast09 looking at TDXd +/- pertuzumab vs THP for 1L therapy of HER2+ MBC; currently enrolling
6
48
196
Who needs adjuvant abemaciclib? A fabulous discussion of this by
@AngieDemichele
with a fantastic algorithm!
#SGBCC2023
@OncoAlert
#bcsm
4
81
192
TROPION-Breast01: Dato-DXd vs TPC in ER+ mBC w/ 1-2 prior lines of chemo
63% w/1L prior chemo
~80% w/prior cdk 4/6i
PFS 6.9 vs 4.9 mo, HR 0.63, p<0.0001
ORR 36.4% vs 22.9%
Fewer grade >=3 AEs w/Dato-DXd c/w TPC
50% Stomatitis,3% ILD
@OncoAlert
#bcsm
#ESMO23
@dradityabardia
1
65
175
Monaleesa-2: AI +/- ribociclib for 1L metastatic HR+ breast cancer. Improvement in OS seen (63.9 mo vs 51.4 mo, HR 0.76); OS now exceeds 5 yrs!
@myESMO
@OncoAlert
0
49
167
Vaccinated! Incredible that vaccines were developed so quickly and wonderful job by
@DanaFarber
to keep employees safe. Thank you!
3
8
148
The FDA has granted accelerated approval to pembrolizumab for use in combination with chemotherapy in the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 as determined by an FDA-approved test.
2
34
146
RIGHT Choice: OS + AI + Ribo vs combo chemo in premenopausal pts for 1L metastatic HR+ dz with measurable dz + visceral dz
PFS: 24 mo vs 12.3 mo (HR 0.54) favoring OS +AI +Ribo
@OncoAlert
#SABCS22
#bcsm
1
55
145
SABR-COMET3 to help answer if SBRT improves OS in pts with oligometastatic dz.
@OncoAlert
#bcsm
2
38
131
PRESS RELEASE from TROPICS-02: Sacituzumab govitecan resulted in a statistically significant improvement in overall survival compared to standard chemotherapy in pretreated metastatic HR+ breast cancer! Great news for patients!
@OncoAlert
#bcsm
0
40
132
KN355: pembro added to chemo improves OS (23.0 vs 16.1 mo, HR 0.73) in CPS≥10 mTNBC in 1L
@myESMO
@OncoAlert
1
47
131
FDA approves abemaciclib in the adjuvant setting for HR+ breast cancer!!! Incredible for our high risk patients with HR+ disease!
Interesting that the approval includes Ki67≥20% given benefits seen in pts with both low and high Ki67.
#bcsm
@OncoAlert
3
55
128
PALLAS: Final analysis does not find any benefit for adjuvant palbociclib. Incredible effort, and investigators are to be congratulated. So much more to be learned from TransPALLAS.
@MichaelGnant
@elmayermd
@OncoAlert
#SABCS21
2
37
126
Wonderful highlights of data in TNBC from SABCS presented by
@CCortiMD
within
@DFCI_BreastOnc
in our triple-negative working group
2
30
121
DAISY: Very interesting data on benefits of TDxd in HER2 3+, HER2 low, HER2 0. Is the ~30% ORR in HER2 0 an issue with testing? We need a more quantitative test for HER2.
No grade 3-5 ILD.
@OncoAlert
#SABCS21
#bcsm
4
38
117
Patritumab deruxtecan (HER3 ADC) in metastatic breast cancer that was HER3+ (113 HR+, 53 TNBC, 14 HER2+) ORR HR+ 30%, 23% TNBC, 43% HER2+ HER3 expression dynamic. 6.6% ILD
#ASCO22
@OncoAlert
0
28
119
monarchE: ctDNA at baseline + 24 mo in a subset of pts
Detection of ctDNA at baseline soon after completion of neo/adjuvant tx: 10/178 (5.6%)
3 of 10 cleared ctDNA + none recurred
7 of 10 had persistence + all recurred
#SABCS23
@OncoAlert
#bcsm
3
32
118
Happy Birthday
@PTarantinoMD
! We are so lucky to have you as part of the
@DFCI_BreastOnc
family!!!
4
1
116
MAINTAIN beautifully designed and presented by
@KalinskyKevin
looked at the question of continuing cdk 4/6i beyond progression showed ET + ribociclib improved PFS compared to ET, 2.7 vs 5.2 mo, majority with fulvestrant as ET
#ASCO22
@OncoAlert
2
23
113
SITC clinical practice guideline on immunotherapy for the treatment of breast cancer now published online in JITC! Very timely!
@JenniferLitton
@EmensLeisha
@OncoAlert
#bcsm
0
40
110
Important presentation of the adjuvant aspirin trial in breast cancer by Wendy Chen from
@DanaFarber
demonstrating no benefit for aspirin therapy in preventing recurrence (HR 1.25)
@OncoAlert
@DanaFarberNews
@DFCI_BreastOnc
#bcsm
0
34
109
Incredible work by
@AnnPartridgeMD
and colleagues to conduct the POSITIVE trial to help us understand the impact of interrupting endocrine therapy to try to conceive--> critical data to help us inform our young breast cancer patients
@DFCI_BreastOnc
@OncoAlert
Finally out in
@NEJM
results from
#POSITIVE
trial showing that temporary interruption of
#EndocrineTherapy
to attempt
#pregnancy
is safe in
#BreastCancer
patients: this is wonderful news…super congrats
@AnnPartridgeMD
@etop_ibcsg
et al!
@OncoAlert
#bcsm
9
190
530
0
26
111
What an incredible
#SABCS23
! A special thanks to the superstar
@VKaklamani
for all are hard work!
3
15
110
10 yr f/u data from APT: TH for pts small, node-negative HER2+ BC
406 pts, 6 distant recurrences, iDFS 91.3%, RFI 96.3%
HER2DX assoc w/ iDFS + RFI
@OncoAlert
@DFCI_BreastOnc
1
30
108
An important study by
@EMittendorfMD
Of those with clinical node- TNBC ~10% of T1ab tumors, + ~15% of T1c tumors will be node + at surgery.
Important implications for who needs preop tx + pembro. Consider axillary US in these pts
@OncoAlert
4
38
107
OlympiA: 1 yr of adj olaparib resulted in significant improvement in iDFS and DDFS in gBRCA high risk breast cancer; while OS not yet significant, very impressive
No excess MDS/AML (0.2% vs 0.3%); no impact on Global QOL scores
Amazing global effort!
@OncoAlert
#bcsm
#ASCO21
0
34
105
Congratulations
@DrEricWiner
. You have built an outstanding breast oncology program
@DanaFarber
and have been an incredible mentor to so many. You will be very missed by us all. We know we will continue to see great things from your leadership
@YaleCancer
.
#bcsm
@OncoAlert
We are proud to announce
@DrEricWiner
as Director
@YaleCancer
and Physician-in-Chief
@SmilowCancer
. Dr. Winer is an internationally renowned expert in breast cancer and president-elect of the American Society of Clinical Oncology
@ASCO
.
@YaleMed
@YNHH
27
49
285
1
10
104
FDA grants regular approval to sacituzumab govitecan for mTNBC with ≥2 lines of chemo (at least 1 for metastatic dz)-- great news that this expands the label! So important for pts!
#bcsm
@OncoAlert
1
36
103
Congratulations
@DrChoueiri
and
@KimmieNgMD
-- two incredible people who will be fabulous on the ASCO Board!!
@DFCI_BreastOnc
@DanaFarber_GU
🗞️ Great news from the
@ASCO
elections! Congrats to
@DrChoueiri
for being elected to the ASCO Board of Directors and to
@KimmieNgMD
for being elected member of the Nominating Committee!
@DanaFarberNews
@DanaFarber
2
6
47
6
10
103
INAVO120 phase 3 study is positive
Fulvestrant + palbociclib +/- inavolisib (oral PI3Ki) in 1L metastatic HR+ breast cancer that progressed on or within 12 mo of adjuvant endocrine therapy in pts with a PI3Km met its primary endpt of PFS
@OncoAlert
#bcsm
2
26
102
KATHERINE Final iDFS and 2nd interim OS Analysis
Adj T-DM1 vs H in pts with RD after preop HER2-directed therapy
f/u 8.4 yrs
iDFS: HR 0.54, absolute benefit 13.7%
OS: HR 0.66, absolute benefit 4.7%, statistically significant p=0.0027
@DFCI_BreastOnc
#SABCS23
@OncoAlert
1
39
101
Very big news! KN522 meets EFS endpoint!! Wonderful that we can improve outcomes for early stage TNBC pts. While there are still unanswered questions (which pts should get IO, what is the optimal chemo backbone, is adjuvant IO needed), this is practice changing!
@OncoAlert
#bcsm
Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) -
2
31
72
3
32
100
Fantastic discussion of APHINITY by
@JavierCortesMD
suggesting a clear benefit for pertuzumab in node + HER2+ BC with improvement in iDFS (4.9% delta) & trend to OS (HR 0.80). In the future, maybe biomarker approaches can help us tailor-- HER2Dx may do this.
@OncoAlert
#bcsm
6
38
100
Data from ATEMPT published in JCO:
*3 yr iDFS for 1 yr of T-DM1 in stage I HER2+ BC: 97.8%
*No difference in rate of clinically relevant toxicities between 1 yr of T-DM1 vs TH
*PROs suggest less neuropathy+ alopecia and better QOL with T-DM1
@OncoAlert
7
41
98
Incredible effort to look at pregnancy and outcomes in pts with BRCAm
Pregnancy without impact on recurrence particularly in pts with BRCA1m
@Oncoalert
#SABCS23
@matteolambe
0
20
98
Outcomes from PALLAS for Stage IIA ER+ BC
4 yr iDFS 92.9% vs 92.1%
No benefit for the addition of palbociclib to endocrine therapy at median f/u 50 mo; very good outcomes in both arms
@AngieDemichele
@elmayermd
#asco
#bcsm
@DFCI_BreastOnc
1
39
95
Jose Baselga made such an incredible impact on drug development and this work impacted the lives of many patients. He also played a key role in mentoring many junior faculty members and helped build many careers. A significant loss. Thoughts are with his family.
Prof. José Baselga has passed on March 21st
Dr.Baselga was an amazing oncologist& researcher who paved the way for many molecular targeted therapies
in2017 was awarded the
@myESMO
Lifetime Achievement Award
Huge loss for the Oncology Community
Our thoughts are with his family
34
140
513
1
10
99
Impressive pCR benefit seen in IMP031 regardless of PD-L1 status with the addition to atezo to anthracycline + taxane chemotherapy (no platinum in backbone); study won't be powered adequately for EFS, and still waiting on KN522 final EFS data
@EMittendorfMD
@OncoAlert
#ESMO20
2
39
96
And the debate begins: should we do local therapy in the setting of metastatic breast cancer?
Pro: Dr. Badwe takes this on (despite the TATA Memorial study showing no benefit in PFS or OS)
#SGBCC2023
@OncoAlert
#bcsm
4
31
97
Phase Ib Study of Ribociclib Plus Fulvestrant and Ribociclib Plus Fulvestrant Plus PI3K-Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer: Unable to find a tolerable RP2D for triplet combinations with PI3Ki due to tox
#bcsm
1
44
95
In pts w/ HR+ mBC (with HER2low, or HER2 ultralow dz) TDXd led to a significant ⬆️ in PFS c/w TPC
Press release out from DESTINY-Breast06
Will be very interested to see the data; will have profound impact on tx sequencing + could put an end to HER2low as a biomarker
NEWS FROM INDUSTRY
Results from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan🧪could become a new standard of care for
#HER2
-low 🧬and HER2-ultralow metastatic
#BreastCancer
patients
➡️showing significant PFS improvements 📈over standard chemotherapy after
3
38
77
3
36
97
PHERGain beautifully presented by
@JavierCortesMD
:
80% with preop HP had early PET response, 38% w/ pCR
95.4% iDFS for the HP arm
3 yr iDFS for those pts w/o chemo (n=86) 98.8%
Early PET response seems to help de-escalate therapy in early HER2+ disease
@OncoAlert
#ASCO23
1
42
95
DESTINY-Breast 03 TDXd vs T-DM1
OS median not reached in either arm, but statistically significantly better with TDXd (HR 0.64)
mPFS 28.8 mo vs 6.8 mo
ORR 78.5% vs 35%
CR 21% vs 9.5%
ILD 15.2% (no grade 4/5 events)
Great presentation by Sara Hurvitz
@OncoAlert
#bcsm
#SABCS22
2
22
93
INAVO120: Fulv + palbo +/- inavolisib in HR+ MBC w/relapse on or w/i 1 yr of adj ET --> impressive data
PFS: 15.0 vs 7.2 mo HR 0.43 , p<0.0001
OS trend HR 0.64
58.6% hyperglycemia (5.6% g3-4)
51.2% stomatitis (5.6% g3-4)
25.3% rash (g3-4)
@jhaveri_komal
@OncoAlert
#SABCS23
2
38
94
POSITIVE: interruption endocrine tx to attempt pregnancy
n=518
94% recovered menses, most resumed during the first 6 months
51% underwent fertility preservation at BC diagnosis
43% underwent ART
No increase in breast cancer events in pts undergoing IVF
#SABCS23
@OncoAlert
0
28
95
Congratulations to
@nlinmd
on receiving the MSCO Distinguished Researcher Award! Nancy has revolutionized therapy for patients with breast cancer brain metastases and this so well deserved!
@DFCI_BreastOnc
10
13
94
Abemaciclib has activity in HR+ brain mets; intracranial CBR 24% in heavily pretreated pts + drug levels in CSF/CNS met similar to plasma
#bcsm
2
34
90
Brilliant discussion by
@curijoey
on KN522
Adding preop pembro to chemo in TNBC improves pCR and EFS, but risk for long term toxicity
Which pts really need preop checkpoint is a critical question?
#ESMOVirtualPlenary
@OncoAlert
#bcsm
0
29
92
Congrats to
@PTarantinoMD
! Wonderful commentary on the limited role for anthracyclines in early stage HER2+ breast cancer.
@curijoey
@JavierCortesMD
0
24
90
Exciting press release: TROPICS-02 met it primary endpoint in pretreated HR+ metastatic breast cancer. Sacituzumab govitecan led to a significant improvement in PFS c/w TPC!
#bcsm
@OncoAlert
1
26
89
Press release just out: monarchE demonstrates adding abemaciclib to endocrine therapy in the adjuvant setting improves outcomes-- wonderful news for patients!!
3
22
89
NATALEE: Adj ribociclib for ER+ BC
iDFS now with 33 mo of f/u
43% completed 3 yrs of ribo
35.5% with early discontinuation
20.7% still on ribociclib
Improvement in iDFS: 90.7vs 87.6% HR 0.749, p=0.0006
@OncoAlert
#SABCS23
5
20
91
BEGONIA: Dato-DXd + Durvalumab in mTNBC update
ORR 79%
mPFS 13.8 mo
>80% with low PDL1 expression (by SP263 or 22C3)
Can IO lead to benefit even in PDL1- tumors when combined with a potent ADC?
#ESMO23
@OncoAlert
#bcsm
0
36
91
Beautiful discussion putting the inavolisib data into context by
@hoperugo
Impressive to get this data out so quickly!
@OncoAlert
#SABCS23
1
19
90
Beautiful presentation by
@elmayermd
of the PACE trial looking to address continuation of palbociclib beyond progression on prior CDK 4/6i
No improvement in PFS seen: 4.6 mo vs 4.8 mo
Interesting signal for fulvestrant + palbo + avelumab (PFS 8.1 mo)
@OncoAlert
#bcsm
#SABCS22
4
23
88
FDA broadens label for adjuvant abemaciclib, removing Ki67 score for patient selection!
Great news, and makes sense given benefit seen irrespective of Ki67 in monarchE
@OncoAlert
#bcsm
0
24
88
Great presentation by
@prat_aleix
on intrinsic subtype + outcomes to ribociclib in mHR+ disease; subtype is an independent prognostic factor; HER2E/lumB/lum A all benefit, basal-like does not; HER2E had greatest relative risk reduction
#SABCS20
@OncoAlert
5
21
88
Gilead announces planned ph 3 trial trial of sacituzumab + pembro vs chemo + pembro in 1L mTNBC-- great that there is work planned to help get sacituzumab to patients in earlier lines of therapy.
#bcsm
1
22
86
Data on retreatment with TDXd after grade 1 ILD from a pooled analysis presented by
@hoperugo
demonstrates that 67% retreated without ILD recurrence
#ESMOBreast24
@OncoAlert
#bcsm
0
31
95
An important day to remind us about the importance of continuing to work towards improving outcomes for our patients with cancer.
@OncoAlert
#bcsm
0
14
88
Congratulations to
@AnnPartridgeMD
of
@DFCI_BreastOnc
for the 2023 Giants of Cancer Care award! She has really helped us understand optimal treatment for young women with breast cancer!! Very well deserved!
Congratulations to
@AnnPartridgeMD
of
@DanaFarber
for being our 2023 Giants of Cancer Care winner in Breast Cancer!
#bcsm
#GiantsCC23
1
2
18
1
9
82
Lots of work is ongoing with ADCs for mTNBC- with new studies for sacituzumab in the 1L setting
#ESMOBreast22
@OncoAlert
#bcsm
0
27
84
Discussion on HER2CLIMB-02 by Valentina Guarneri leaving us with the question of what the optimal sequencing is for our patients with metastatic HER2+ BC
@OncoAlert
#SABCS23
1
32
84
Beautiful presentation by
@nlinmd
on OP-1250 (palezestrant) in HR+ mBC
RP2D
42% >= 3L prior tx
CBR 40%
PFS 4.6 mo (5.6mo ESR1m)
@OncoAlert
@DFCI_BreastOnc
#ESMO23
1
32
84
Outstanding presentation by
@AnnPartridgeMD
on the POSITIVE data looking at outcomes for women w/HR+ BC holding adjuvant ET to try to conceive
Temporary interruption does not impact short-term disease outcomes (median f/u 41 mo)
@OncoAlert
@DFCI_BreastOnc
#SABCS22
#bcsm
1
20
81
Sacituzumab Govitecan has ORR 31%, PFS 5.5 mo in pretreated mHR+ breast cancer. Awaiting data now from TROPICS-02.
@KalinskyKevin
@ABhealer108
#bcsm
1
6
18
1
18
80
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0 ---now online in JCO. Thanks to all the hard work in the NCI breast working group on this!
@LGM_Biostats
@OncoAlert
#bcsm
0
36
79
Impressive results for sacituzumab in the ASCENT trial: HR 0.41 for PFS when c/w SOC in mTNBC (and improved OS, ORR)
3
29
79
World Cancer Day is a reminder of how much we can do together to fight cancer and improve outcomes for our patients
@OncoAlert
@DanaFarberNews
1
9
79
Excellent discussion of systemic therapy management of gBRCA pts by Andrew Tutt
@SGBCC2023
#bcsm
@OncoAlert
1
33
79
ASCENT: benefit with SG versus TPC is irrespective of level of Trop-2 expression; higher efficacy outcomes in pts tx'd with SG with medium/high Trop-2 H-score (vs low Trop-2 H-score) versus those treated with TPC; SG benefit regardless of gBRCA status
#SABCS2020
@OncoAlert
1
24
79
Tucatinib penetrates the CSF with similar drug levels in CSF and plasma-- important for patients with brain metastases.
Will be important to learn if this agent can also prevent new brain mets.
@OncoAlert
#ASCO21
Congrats to Drs. Erica Stringer-Reasor, Barbara O'Brien,
@rashmikmurthy
for
@theTBCRC
study 049: Tucatinib + cape + tras for HER2+ LMD. 1st demonstration of tucatinib penetration into CSF, median CSF:plasma ratio 0.83 at steady state. Study still enrolling-NCT03501979
#ASCO21
1
13
60
0
22
76
DESTINY BREAST-02 press release: T-DXd improves PFS and OS in pretreated metastatic HER2+ BC c/w cape + H or L; confirming benefits seen in single arm DB01 study in pretreated pts. Nice to have phase 3 data!
@OncoAlert
#bcsm
1
21
79
DESTINY BREAST 03: TDxd vs T-DM1
Pts with baseline treated brain mets PFS 15 mo vs 3 mo
ORR 67% vs 20% in pts with BMs
28% iORR vs 2.8% iORR for T-DM1
Nice to see benefit seen across the patient subgroups
@OncoAlert
#SABCS21
#bcsm
0
25
78
Great editorial by
@EMittendorfMD
on the ability of peritumoral lidocaine administered before surgery to impact iDFS and OS in patients with early-stage breast cancer
Interesting work by Badwe and colleagues.
@DFCI_BreastOnc
@OncoAlert
#bcsm
2
24
78
gBRCA2m associated inferior outcomes with cdk 4/6i; Rb1 monoallelic loss associated with less benefit to cdk 4/6i
@OncoAlert
#bcsm
#SABCS21
2
21
77
NATALEE
Adjuvant Ribo in early stage HR+ BC
Median f/u 34.0 months
57% at ≥2 ys, 20% at 3 yrs
iDFS: 90.4% vs 87.1% HR 0.748 p=0.0014
Stage 2 HR 0.76, Stage 3 HR 0.74
DDFS: 90.8% vs 88.6% HR 0.739
G≥3 Tox: Neutropenia: 43.8% Liver AEs: 8.3%
#ASCO23
@OncoAlert
1
30
77
TBCRC049:Tucatinib+ cape+ trastuzumab for LMD demonstrates mOS 10mo, and metabolite of tucatinib seen in plasma and CNS
@OncoAlert
#SABCS21
#bcsm
0
30
76
Brilliant talk by
@jsparano
on which pts with early stage breast cancer need chemotherapy; wonderful to hear about genomic assays and chemo selection from a leader in this field who put the complex data all into perspective
@harvardmed
@DFCI_BreastOnc
#bcsm
3
31
73
DatoDxd in pretreated metastatic TNBC- ORR 34% (ORR 52% in pts naive to TopoIi). Exciting data for a novel TROP2 ADC.
Great presentation by Ian Krop
@DanaFarber
@OncoAlert
#bcsm
#SABCS21
1
14
76
Very helpful discussion by Cristina Saura on how to think about adjuvant therapies in pts with gBRCAm
Could we consider sequential adjuvant abemaciclib after olaparib in high-risk pts with ER+ BC and gBRCAm?
@oncoalert
#bcsm
#ESMOBreast24
1
21
78
UNIIRAD: ph 3 Adj ET +/- everolimus in high risk HR+HER2- breast cancer, no improvement in DFS: HR 0.95, ~54% early discontinuation. Important work even though lack of benefit seen.
@OncoAlert
#bcsm
@myESMO
3
20
75
Great to see the AMEERA-3 study now published in
@JCO_ASCO
looking at oral amcenestrant vs endocrine monotherapy. Important lessons learned about benefits of oral SERDS in ER+ MBC with larger benefits seen in pts w/ ESR1 mutations.
@OncoAlert
#bcsm
1
28
74
The Optimice-pCR trial will take TNBC pts who achieved pCR to chemo + IO and randomize them to 27 wks of pembro or to observation. So it will have a surveillance arm post pCR. And is a non-inferiority design.
#bcsm
@Dr_RShatsky
@ErikaHamilton9
@OncoAlert
@stolaney1
@IlanaSchlam
If pCR is achieved, do these patients get adj IO? Is there an arm for surveillance alone post pCR?
Data in NSCLC
#CM816
with just 3 cycles of IO in neoadj is very exciting/approved. Similar approach in de-escalating/selecting pts that might not need adj rx would be amazing!
2
0
1
5
20
75
As always
@GeorgeSledge51
provides a thoughtful and insightful discussion. monarchE finds adjuvant abemaciclib results in an absolute 3.5% improvement in iDFS. Early data, but exciting to see such benefit for our high risk HR+ pts.
@OncoAlert
@LillyPad
@DrStephenjohns2
#bcsm
1
17
73
IMPassion050: no benefit from adding atezolizumab to preop ACTHP in terms of pCR (in ITT and PDL1+)
@OncoAlert
@myESMO
#bcsm
2
31
74